Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP)
in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir
(DTG)-based antiretroviral therapy (ART) and HIV-uninfected children not on ART. All children
will be malaria-uninfected at the time of enrollment.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Makerere University Yale University